Certainly Health vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC S23 doctor booking with upfront cost guarantees via ML price prediction; $2.3M Pacific 8/YC seed Dec 2023 solving 57% surprise bills and 38% delayed care competing with Zocdoc for healthcare price transparency booking.
About
Certainly Health is a San Francisco-based healthcare price transparency marketplace — backed by Y Combinator (S23) with $2.3 million in seed funding in December 2023 from Pacific 8 Ventures, Y Combinator, institutional investors, and angels — providing patients with a doctor booking platform that shows upfront out-of-pocket costs using machine learning to predict and guarantee healthcare spending before appointments, addressing the surprise medical bill crisis where 57% of Americans have received unexpected bills and 38% delay care due to cost uncertainty. Founded in 2023 by Daryl Sew and Kevin Chiu (Stanford graduate, former Uber engineer, and Uber Health founding member who grew that program to $100 million in 2 years), Certainly Health enables patients with insurance to book doctors while seeing the actual cost they will owe — not the sticker price.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.